疾病类型和临床指标对CMIA抗HCV抗体检测的影响

doi:10.3969/j.issn.1673-8640.2023.03.016

检验医学 ›› 2023, Vol. 38 ›› Issue (3): 287-290.DOI: 10.3969/j.issn.1673-8640.2023.03.016

疾病类型和临床指标对CMIA抗HCV抗体检测的影响

何鑫¹, 李燕平²()

1.兰州大学第一临床医学院，甘肃兰州 730000
2.兰州大学第一医院检验科，甘肃兰州 730000

收稿日期:2021-03-29 修回日期:2022-06-03 出版日期:2023-03-28 发布日期:2023-05-24
通讯作者: 李燕平
作者简介:李燕平，E-mail：Liyanping814@sina.com。
何鑫，女，1993年生，学士，主要从事临床血液学检验工作。

Influence of disease types and clinical indexes on the CMIA determination results of anti-HCV antibody

HE Xin¹, LI Yanping²()

1. The First School of Clinical Medicine of Lanzhou University，Lanzhou 730000，Gansu，China
2. Department of Clinical Laboratory，the First Hospital of Lanzhou University，Lanzhou 730000，Gansu，China

Received:2021-03-29 Revised:2022-06-03 Online:2023-03-28 Published:2023-05-24
Contact: LI Yanping

摘要/Abstract

摘要： 目的探讨化学发光微粒子免疫测定法（CMIA）测定抗HCV抗体产生灰区结果的影响因素。方法选取采用CMIA进行抗HCV抗体检测，且结果位于灰区（S/CO值为1.0~5.0）的患者183例（灰区组），包括恶性肿瘤33例、乙型肝炎16例、胆囊炎16例、胆囊结石13例、良性肿瘤13例、肝硬化11例、胆管结石9例、胆管炎9例，其他疾病63例。以抗HCV抗体检测结果为阴性（S/CO值<1.0）的健康体检者33名作为正常对照组。采用逆转录聚合酶链反应（RT-PCR）检测所有患者的HCV RNA。收集所有研究对象的临床资料和实验室指标检测结果，记录相应的酶联免疫吸附试验（ELISA）和电化学发光法抗HCV抗体检测结果。采用多元线性回归分析探讨抗HCV抗体检测结果的影响因素。结果灰区组HCV RNA检测结果均为阴性。CMIA和电化学发光法与RT-PCR的符合率为100.00%，ELISA与RT-PCR的符合率为97.81%。多元线性回归分析结果显示，良性肿瘤（t=2.080，P=0.039）可使CMIA检测抗HCV抗体的S/CO值升高，渗透压升高（t=-2.238，P=0.027）可使CMIA检测抗HCV抗体的S/CO值降低，其他指标对CMIA检测抗HCV抗体无显著影响（P>0.05）。灰区组血清离子渗透压与正常对照组比较，差异无统计学意义（P>0.05）。结论采用CMIA检测有良性肿瘤史患者的样本时S/CO值可能会升高，导致产生灰区结果。

关键词: 丙型肝炎病毒, 化学发光微粒子免疫测定法, 抗体, 灰区

Abstract: Objective To investigate the influencing factors of grey-zone results in anti-hepatitis C virus（HCV） antibody determination by chemiluminescence microparticle immunoassay（CMIA）. Methods Totally，183 patients in the grey-zone（S/CO value was 1.0-5.0）（grey-zone group） were enrolled for anti-HCV antibody determination by CMIA. There were 33 cases of malignant tumors，16 cases of hepatitis B，16 cases of cholecystitis，13 cases of gallstones，13 cases of benign tumors，11 cases of liver cirrhosis，9 cases of bile duct stones，9 cases of cholangitis and 63 cases of other diseases. Totally，33 healthy subjects with negative results of anti-HCV antibody（S/CO value <1.0） were enrolled as control group. Reverse transcription-polymerase chain reaction（RT-PCR） was used to determine HCV RNA. The clinical data of all the patients and the laboratory determination results of all the subjects were collected，and the anti-HCV antibody determination results by enzyme-linked immunosorbent assay（ELISA） and electrochemiluminescence immunoassay were recorded. Multiple linear regression analysis was used to investigate the influencing factors of anti-HCV antibody determination results. Results The results of HCV RNA determination in grey-zone group were negative. The consistency of CMIA and electrochemiluminescence immunoassay with RT-PCR was 100.00%，and the consistency of ELISA with RT-PCR was 97.81%. The results of multiple linear regression analysis showed that the S/CO value of anti-HCV antibody determined by CMIA could be increased by benign tumors（t=2.080，P=0.039） and be decreased by osmolality（t=-2.238，P=0.027）. The other indicators had no effect on the determination of anti-HCV antibody by CMIA（P>0.05）. There was no statistical significance in serum osmolality between grey-zone group and control group（P>0.05）. Conclusions When using CMIA to determine the samples from patients with a history of benign tumors，the S/CO value may increase，resulting in grey-zone results.

Key words: Hepatitis C virus, Chemiluminescence microparticle immunoassay, Antibody, Grey-zone

中图分类号:

R373.2

何鑫, 李燕平. 疾病类型和临床指标对CMIA抗HCV抗体检测的影响[J]. 检验医学, 2023, 38(3): 287-290.

HE Xin, LI Yanping. Influence of disease types and clinical indexes on the CMIA determination results of anti-HCV antibody[J]. Laboratory Medicine, 2023, 38(3): 287-290.

图/表 2

参考文献 15

[1]	World Health Organization.Global hepatitis report 2017[Z]. Geneva: World Health Organization, 2017.
[2]	MUKHERJEE R, BURNS A, RODDEN D, et al. Diagnosis and management of hepatitis C virus infection[J]. J Lab Autom, 2015, 20(5):519-538. DOI PMID
[3]	KRAJDEN M, ZIERMANN R, KHAN A, et al. Qualitative detection of hepatitis C virus RNA:comparison of analytical sensitivity,clinical performance,and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay[J]. J Clin Microbiol, 2002, 40(8):2903-2907. DOI URL
[4]	European Association for the Study of the Liver. EASL clinical practice guidelines:management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. DOI URL
[5]	KAO H H, CHEN K S, LIN C L, et al. Utilization of signal-to-cutoff ratio of hepatitis C virus antibody assay in predicting HCV viremia among hemodialysis patients[J]. Nephron, 2015, 130(2):127-133. DOI URL
[6]	HA J, PARK Y, KIM H S. Signal-to-cutoff ratios of current anti-HCV assays and a suggestion of new algorithm of supplementary testing[J]. Clin Chim Acta, 2019, 498:11-15. DOI PMID
[7]	李瑞兰, 李忠平, 樊忠杰, 等. HCV抗体检测临界值附近样本传播HCV风险的研究[J]. 临床输血与检验, 2008, 10(1):31-35.
[8]	王慜杰, 韩彬彬, 孙麟坤, 等. 肿瘤患者丙肝病毒抗体结果在HCV现症感染诊断中的临床价值[J]. 中华检验医学杂志, 2018, 41(6):4.
[9]	中国丙型病毒性肝炎医院感染防控指南(2021年版)[J]. 中国感染控制杂志, 2021, 20(6):487-493.
[10]	ISMAIL A A. Interference from endogenous antibodies in automated immunoassays:what laboratorians need to know[J]. J Clin Pathol, 2009, 62(8):673-678. DOI URL
[11]	STEVENSON D L, HARRIS A G, NEAL K R, et al. The presence of rheumatoid factor in sera from anti-HCV positive blood donors interferes with the detection of HCV-specific IgM. Trent HCV study group[J]. J Hepatol, 1996, 25(5):621-626. PMID
[12]	VIANI R M, ARANETA M R, SPECTOR S A. Parallel rapid HIV testing in pregnant women at Tijuana General Hospital,Baja California,Mexico[J]. AIDS Res Hum Retroviruses, 2013, 29(3):429-434. DOI URL
[13]	MOLL J, ISAILOVIC N, DE SANTIS M, et al. Rheumatoid factors in hepatitis B and C infections:connecting viruses,autoimmunity,and cancer[J]. Isr Med Assoc J, 2019, 21(7):480-486.
[14]	GIOVANELLA L, CERIANI L, LUMASTRO C, et al. False-positive serum chromogranin A assay due to heterophile antibody interference[J]. Clin Chim Acta, 2007, 379(1-2):171-172. PMID
[15]	SOARES D G, MILLOT F, LACROIX I, et al. Heterophile antibody interference led to unneeded chemotherapy in a testicular cancer patient[J]. Urol Case Rep, 2016, 9:1-3. DOI PMID

项目	VIF值^①	β值	标准误	标准化β值	t值	P值
常量		3.212	0.536		5.949	0.000
良性肿瘤史	1.001	0.566	0.272	0.160	2.080	0.039
离子渗透压	1.001	-0.004	0.002	-0.172	-2.238	0.027

项目	VIF值^①	β值	标准误	标准化β值	t值	P值
常量		3.212	0.536		5.949	0.000
良性肿瘤史	1.001	0.566	0.272	0.160	2.080	0.039
离子渗透压	1.001	-0.004	0.002	-0.172	-2.238	0.027

疾病类型和临床指标对CMIA抗HCV抗体检测的影响

Influence of disease types and clinical indexes on the CMIA determination results of anti-HCV antibody

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 15

相关文章 15

编辑推荐

Metrics

方法	阳性/例	阴性/例	符合率/%
RT-PCR	0	183
ELISA	4	179	97.81
电化学发光法	0	183	100.00
CMIA	0	183	100.00

[1]	孙信林, 叶星明, 李倩, 赵丽君. 支气管镜检查联合痰TB-RNA、血清TB-SA检测诊断菌阴肺结核[J]. 检验医学, 2023, 38(9): 870-873.
[2]	段丽丽, 蒋唱, 周冬梅. PLR在抗核抗体阳性强直性脊柱炎患者中的临床价值[J]. 检验医学, 2023, 38(7): 669-674.
[3]	倪佳佳, 龙钰, 张丽, 杨青青, 刘义庆, 寇纯嘉, 李静怡, 李舒祺, 张海清. 生物素、异嗜性抗体、甲状腺激素自身抗体干扰甲状腺功能检测1例报道[J]. 检验医学, 2023, 38(6): 599-602.
[4]	肖秀美, 梁超, 刘彩红, 李晓光. 新型冠状病毒中和抗体与特异性抗体检测结果一致性分析[J]. 检验医学, 2023, 38(4): 352-356.
[5]	张嘉懿, 郭文伟, 沈永明, 娜仁, 崔小健, 司萍. 光激化学发光法检测儿童乙型肝炎核心抗体最佳临界值探讨[J]. 检验医学, 2023, 38(3): 291-293.
[6]	范列英. 膜性肾病生物标志物的研究现状与应用展望[J]. 检验医学, 2023, 38(12): 1111-1114.
[7]	孙林成, 李建锋, 程维丽, 姬攀云. 抗PLA2R IgG4抗体、PLA2R IgG4/IgG比值在原发性膜性肾病预后评估中的价值[J]. 检验医学, 2023, 38(12): 1115-1120.
[8]	杨晓, 李恩灵, 吴丽霞, 戴颖欣, 王之青, 黄昊, 郑冰. 胞质型抗核抗体对间接免疫荧光法检测抗中性粒细胞胞质抗体的影响[J]. 检验医学, 2023, 38(12): 1135-1140.
[9]	项瑾, 刘爱平, 胡尧, 吴之源, 曹国君, 关明. 新型冠状病毒肺炎患者抗核抗体谱分析和血清加热灭活对检测的影响[J]. 检验医学, 2023, 38(12): 1141-1146.
[10]	成宇, 徐臻, 陆柳, 丁梦蕾, 虞珊珊, 宗明, 范列英. 新型冠状病毒肺炎患者血清抗ACE-2抗体表达及其影响因素分析[J]. 检验医学, 2023, 38(12): 1147-1152.
[11]	游延军, 张欢, 向乾银, 曹长春, 王健, 曾红, 魏元敏, 吴斌, 黄敬双, 季纯宇, 代苗, 秦枫. 原发性膜性肾病标志物抗PLA2R抗体检测方法比较[J]. 检验医学, 2023, 38(12): 1153-1156.
[12]	王丽, 陈琳, 黄卓春. 易误判的ANA荧光模型1例报道[J]. 检验医学, 2023, 38(12): 1157-1159.
[13]	邓卓娜, 杨令芝, 黄茂, 王烤, 宁旭. 疑似疱疹病毒抗体引起HIV初筛假阳性1例报道[J]. 检验医学, 2023, 38(10): 1006-1008.
[14]	段飞云, 胡汝源, 赵丽娜. 2016—2020年大理州20~40岁女性麻疹抗体水平监测和分析[J]. 检验医学, 2023, 38(10): 946-950.
[15]	刘欣, 杨梅, 崔京京, 陈芳, 郭亚平. 新生儿自身免疫性肝病1例报道及文献复习[J]. 检验医学, 2023, 38(1): 100-102.